The OHSU Knight Cancer Institute is a pioneer in personalized cancer treatment and research, led by Dr. Brian Druker, whose development of Gleevec transformed Chronic Myeloid Leukemia from a fatal disease to a manageable one and proved that targeted therapies can work. The institute focuses on precision oncology, the early detection, prevention, and treatment of cancer, and creating a welcoming and supportive environment for its caregivers, researchers, and support personnel. Knight affiliates subscribe to three guiding principles: we are bold, we are supportive, and we work as a connected team in our fight to end cancer as we know it.
Every Knight Cancer employee is expected to embody our guiding principles:
- We act BOLDLY—Breakthroughs require pushing the boundaries of science, exploring new frontiers, and thinking differently
- We SUPPORT each other—Respect leads to trust, which leads to excellence
- We work as a CONNECTED team—We must leverage our collective brain power to conquer cancer because no one individual can do it alone